Skip to main content

Dopamine agonists in the treatment of prolactinoma: are they still first choice?

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Dopamine agonist therapy has been the cornerstone treatment for prolactinoma since the 1970s, replacing surgery in the primary management of this condition. These agents are effective in the management of prolactin excess, have a low side‐effect profile, and in some cases may even be curative. However, recent studies of high dose dopamine agonists used in Parkinson's disease have raised the possibility that these drugs may be associated with cardiac valvulopathy. This paper discusses the modern use of dopamine agonists in a patient with prolactinoma.

Keywords: cardiac valvulopathy; dopamine agonist; prolactin; prolactinoma

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1445-5994.2010.02410.x

Affiliations: Reproductive Endocrine Group at Fertility Associates, Auckland, New Zealand

Publication date: 2011-02-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more